Deals
Express Scripts Sells Unit With Ties to a $35,000-a-Vial Drug
- Investor Jim Chanos has said he’s shorting companies’ stocks
- Private equity firm Avista to buy United BioSource unit
Photographer: Bloomberg
This article is for subscribers only.
Express Scripts Holding Co. is trimming some of its ties to a $35,000-a-vial medicine made by Mallinckrodt Plc by selling a unit that helps patients access some high-priced drugs.
Avista Capital Partners, a private equity firm, will buy Express Scripts’ United BioSource division, the firms said in a statement. United BioSource’s website says it helps “maximize product access and commercialization,” helps drug companies “overcome access and adherence challenges” and provides drug testing services.